Trial Profile
A Phase III Double-Blind, Randomized, Basic treatment-Controlled Study to Evaluate the Safety and Efficacy of pUDK–HGF in Subjects With rest pain of Critical Limb Ischemia
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Aug 2018
Price :
$35
*
At a glance
- Drugs PUDK HGF (Primary)
- Indications Chronic limb-threatening ischemia
- Focus Registrational; Therapeutic Use
- Sponsors Humanwell Healthcare
- 07 Aug 2018 New trial record